We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AAMI
201
Acadian Asset Management
AAMI
$2.94B
| $20.1M | 0.08% |
+416,498
| New | +$18.6M |
|
202
Kura Oncology
KURA
$929M
| $19.7M | 0.08% |
2,224,590
+1,121,228
| +102% | +$7.99M |
|
203
CNO Financial Group
CNO
$4.97B
| $19.6M | 0.08% |
494,955
+2,950
| +0.6% | +$113K |
|
204
Exelixis
EXEL
$14.1B
| $19.5M | 0.08% |
472,820
-535,153
| -53% | -$21.5M |
|
205
InterDigital
IDCC
$6.7B
| $19.4M | 0.08% |
56,137
+27,088
| +93% | +$7.36M |
|
206
Cavco Industries
CVCO
$4.44B
| $19.2M | 0.08% |
33,038
-752
| -2% | -$368K |
|
207
Mercado Libre
MELI
$93B
| $19M | 0.08% |
+8,125
| New | +$19.5M |
|
208
Napco Security Technologies
NSSC
$1.3B
| $18.8M | 0.07% |
438,327
+8,004
| +2% | +$278K |
|
209
Cardinal Health
CAH
$53.8B
| $18.7M | 0.07% |
118,961
+9,116
| +8% | +$1.41M |
|
210
InvenTrust Properties
IVT
$2.85B
| $18.6M | 0.07% |
651,003
+30,661
| +5% | +$869K |
|
211
Church & Dwight Co
CHD
$23.4B
| $18.4M | 0.07% |
210,485
-184,393
| -47% | -$17.3M |
|
212
OFG Bancorp
OFG
$2.22B
| $18.3M | 0.07% |
419,779
-47,183
| -10% | -$2.07M |
|
213
Columbia Sportswear
COLM
$3.23B
| $18.1M | 0.07% |
345,632
-14,671
| -4% | -$825K |
|
214
KB Home
KBH
$3.53B
| $18M | 0.07% |
283,250
-37,599
| -12% | -$2.27M |
|
215
Tandem Diabetes Care
TNDM
$1.16B
| $18M | 0.07% |
1,481,953
+50,646
| +4% | +$686K |
|
216
Myriad Genetics
MYGN
$523M
| $17.7M | 0.07% |
2,442,912
+1,492,405
| +157% | +$8.86M |
|
217
Andersons Inc
ANDE
$2.53B
| $17.4M | 0.07% |
438,219
+271,451
| +163% | +$10.5M |
|
218
Old Republic International
ORI
$10.5B
| $17.3M | 0.07% |
408,124
-4,534
| -1% | -$175K |
|
219
Scansource
SCSC
$1.12B
| $17.2M | 0.07% |
389,915
+154,518
| +66% | +$6.58M |
|
220
Vita Coco
COCO
$3.87B
| $17M | 0.07% |
401,446
+268,338
| +202% | +$9.95M |
|
221
Sonic Automotive
SAH
$3.24B
| $17M | 0.07% |
223,396
-21,354
| -9% | -$1.7M |
|
|
FISV
222
Fiserv Inc
FISV
$27.9B
| $16.9M | 0.07% |
+130,923
| New | +$18.8M |
|
223
Pacira BioSciences
PCRX
$1.06B
| $16.8M | 0.07% |
652,580
-332,162
| -34% | -$8.16M |
|
|
CTRA
224
DELISTED
Coterra Energy
CTRA
| $16.8M | 0.07% |
710,610
-106,184
| -13% | -$2.56M |
|
225
Maplebear
CART
$10.3B
| $16.7M | 0.07% |
455,050
-45,340
| -9% | -$2.09M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.